Login

Tag: deceptive promotion

deceptive promotion

Regulatory/FDA

FDA To Study Consumer, HCP Ability to Spot Deceptive Drug Ads

FDA To Study Consumer, HCP Ability to Spot Deceptive Drug Ads

Dec. 22, 2017 — The FDA recently announced that it was planning to study whether consumers and healthcare professionals have the ability to “spot and report” deceptive prescription drug promotion practices (https://www.gpo.gov/fdsys/pkg/FR-2017-12-12/pdf/2017-26704.pdf). The FDA’s Office of Prescription Drug Promotion (OPDP), which issued the lowest number of enforcement letters ever in 2017, appears to be looking […]

Read more

Regulatory/FDA

FDA Will Study Consumer and HCP Ability to Identify Deceptive Drug Promotion

FDA Will Study Consumer and HCP Ability to Identify Deceptive Drug Promotion

Jan. 4, 2017 – The FDA will examine whether consumers and health care professionals (HCPs) can identify deceptive claims in prescription drug promotion, according to a notice published in today’s Federal Register. Results of the study could lead to an expansion of the FDA’s Bad Ad program to include consumer reporters. Although empirical research has […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC gifts to physicians HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines